DelMar Pharmaceuticals Inc  

(Public, NASDAQ:DMPI)   Watch this stock  
Find more results for DMPI
+0.062 (7.69%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.82 - 0.87
52 week 0.78 - 5.39
Open 0.84
Vol / Avg. 1.32M/694,726.00
Mkt cap 18.63M
P/E     -
Div/yield     -
EPS -0.68
Shares 21.60M
Beta 1,249.13
Inst. own 17%
Feb 12, 2018
Q2 2018 DelMar Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 14, 2017
Q1 2018 DelMar Pharmaceuticals Inc Earnings Call
Nov 13, 2017
Q1 2018 DelMar Pharmaceuticals Inc Earnings Release
Oct 4, 2017
Q4 2017 DelMar Pharmaceuticals Inc Earnings Call
Sep 11, 2017
DelMar Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 1, 2017
Q4 2017 DelMar Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.66% -113.29%
Return on average equity -326.85% -
Employees 4 -
CDP Score - -


999 Broadway W Suite 720
+1-604-6295989 (Phone)
+1-604-6085685 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Officers and directors

Erich Mohr Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Jeffrey A. Bacha President, Chief Operating Officer, Director
Age: 48
Bio & Compensation  - Reuters
Saiid Zarrabian Interim Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Scott Praill Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
John K. Bell Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Lynda Sarah Cranston Independent Director
Age: 68
Bio & Compensation  - Reuters
Robert J. Toth Jr. Independent Director
Age: 53
Bio & Compensation  - Reuters